Skye Bioscience to Showcase Nimacimab-GLP-1 Combo Strategy at Therapeutics Summit
Event summary
- Skye Bioscience will present at the GLP-1-Based Therapeutics Summit in Boston on April 16, 2026.
- CEO Punit Dhillon will discuss the combination of nimacimab and GLP-1 agonists for obesity treatment.
- Nimacimab is a peripherally-restricted CB1 receptor inhibitor designed to avoid neuropsychiatric side effects.
- Phase 2a trial (NCT06577090) is assessing nimacimab's combination with semaglutide (Wegovy) for obesity.
- Skye aims to position nimacimab as an orthogonal add-on therapy for GLP-1-treated patients.
The big picture
Skye Bioscience's presentation highlights the growing interest in combination therapies for obesity, particularly as GLP-1 agonists face limitations in sustained weight loss. The company's focus on peripherally-restricted CB1 inhibition represents a strategic pivot from earlier failed CB1-targeting drugs, potentially offering a safer, more effective treatment option. The obesity market remains highly competitive, with major players like Novo Nordisk and Eli Lilly dominating, making differentiation and clinical success critical for Skye's long-term viability.
What we're watching
- Combination Therapy Efficacy
- How the additive effects of nimacimab and GLP-1 agonists will impact long-term weight management outcomes.
- Regulatory Pathway
- The pace at which Skye can advance nimacimab through clinical trials and secure regulatory approval.
- Market Differentiation
- Whether Skye can position nimacimab as a distinct, commercially viable option in the crowded obesity treatment space.
Related topics